Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Voluntarily provided informed consent~* Meet diagnostic criteria for idiopathic Parkinson's Disease~* On L-Dopa and oral ropinirole~* If female of child-bearing potential, willing to practice contraception from time of informed consent to Follow-Up Visit~Key Exclusion Criteria:~* Pregnant, breastfeeding, or planning to become pregnant~* Active epilepsy within the past year~* Severe dementia or cognitive impairment~* Donated or lost \> 400 mL of blood within 1 month prior to Screening~* History of alcohol or substance use disorder within the prior 12 months~* Recent episodes of moderate to severe dizziness or syncope~* Definite or suspected hypersensitivity to ropinirole or ethylene vinyl acetate~* Used any other investigational drug within 60 days or 5 half-lives prior to Screening, or plan to take any such drug any time during the study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Requip; One Ropinirole Implant
- Cohort 2 (Type: EXPERIMENTAL): Requip; Two Ropinirole Implants
- Cohort 3 (Type: EXPERIMENTAL): Requip; Three Ropinirole Implants
- Cohort 4 (Type: EXPERIMENTAL): Requip; Four Ropinirole Implants

Based on this trial design, predict the completion outcome and termination type (if applicable).